Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Boyd Vaziri

Ophthalmology Fort Myers, FL Medical Doctor

NPI 1083685234 CMS profile 621757

9617 Gulf Research Ln, Fort Myers, FL 33912

Open in the dashboard

General payments

$5,562

151 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Boyd Vaziri of Fort Myers, FL is reported in the CMS Open Payments database as having received $5,562 across 151 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $818 19
2024 General $713 16
2023 General $1,092 26
2022 General $898 29
2021 General $1,345 30
2020 General $211 10
2019 General $485 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Boyd Vaziri
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Boyd Vaziri were reported at $818. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Boyd Vaziri Ophthalmology median Middle half National median
2019 $485 $258 $104–$655 $163
2020 $211 $126 $45–$321 $114
2021 $1,345 $205 $76–$534 $132
2022 $898 $266 $100–$678 $149
2023 $1,092 $308 $117–$745 $160
2024 $713 $340 $127–$846 $164
2025 $818 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,493 46 payments
  2. Medtronic, Inc. $556 4 payments
  3. Bausch & Lomb Americas Inc. $520 28 payments
  4. Johnson & Johnson Vision Care, Inc. $367 7 payments
  5. NuVasive, Inc. $366 2 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $363 17 payments
  7. NotalVision $236 1 payment
  8. TissueTech, Inc. $219 6 payments
  9. New World Medical,Inc. $208 1 payment
  10. Sun Pharmaceutical Industries Inc. $156 3 payments
  11. Other $1,078 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,327 150 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $236 1 payment
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $392 2 payments
  2. VYZULTA $374 27 payments
  3. Acuvue $367 7 payments
  4. DAILIES $343 9 payments
  5. MIEBO $218 7 payments
  6. Ahmed Glaucoma Valve $208 1 payment
  7. Clearpath $208 1 payment
  8. Via360 $208 1 payment
  9. Streamline $208 1 payment
  10. Kahook Dual Blade $208 1 payment
  11. Other $3,694 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

622

Median for Ophthalmology: 891

Drug cost

$62,534

Median for Ophthalmology: $68,233

Branded share of claims

22.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xiidra Lifitegrast Brand 14 $24,328
Restasis Cyclosporine Brand 21 $19,560
Cyclosporine Generic 13 $8,509
Ketorolac Tromethamine Generic 54 $2,020
Doxycycline Hyclate Generic 82 $1,961
Latanoprost Generic 129 $1,366
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 35 $1,328
Prednisolone Acetate Generic 35 $932
Timolol Maleate Generic 52 $874
Mupirocin Generic 99 $663

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$279,231

Medicare's payments for the services billed

Medicare patients

1,248

Average age 76

Services billed

3,118

711 women, 537 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 50%
Ischemic heart disease 34%
Diabetes 21%
Atrial fibrillation 20%
Chronic kidney disease 19%
Depression 19%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $57
$57 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $34
$34 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $30
$30 — —
MIEBO
  • Bausch & Lomb Americas Inc. $17
$17 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $17
$17 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record